17 / 61
Notes:
Volume10, Issue 12 (Suppl)
J Proteomics Bioinform, an open access journal
ISSN: 0974-276X
Page 73
conferenceseries
.com
World Biomarkers & Pharma Biotech 2017
December 07-09, 2017
December 07-09, 2017 | Madrid, Spain
&
20
th
International Conference on
PHARMACEUTICAL BIOTECHNOLOGY
9
th
WORLD BIOMARKERS CONGRESS
JOINT EVENT ON
Blood-based biomarkers of neuropsychiatric symptoms in Alzheimer’s: Inflammation, vascular
risks, gender and APOEε4 status
James Hall
University of North Texas Health Science Center, USA
Background:
The presence of neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) is frequent, difficult to treat, the
largest risk for nursing home placement and a primary source of caregiver stress. This research is directed toward identifying
blood-based biomarkers that could be useful in identifying those individuals with Alzheimer’s who are at greater risk for
developing NPS.
Methods:
Data were analyzed on 300 AD participants from the TARC cohort. Blood-based markers of cardiovascular risk,
inflammation and microvascular pathology were assayed. NPS were assessed using NPI-Q and the Geriatric Depression Scale.
Results:
Total cholesterol and homocysteine were positively related to NPS. Cholesterol was a positive marker for total NPS
and symptoms of hyperactivity, psychosis, affective and apathy among men. IL-15 and IL-1ra were negatively associated with
neuropsychiatric symptoms and homocysteine positively associated for females. Total cholesterol was related to NPS in males
regardless of APOEε4 status. IL15 was found to be negatively and significantly related to NPS for female APOEε4 carriers only.
High TC in males was related to number and type of NPS. Lower MIF was a strong predictor of depression and TNFα predicted
apathy. For females MIF, ICAM and CRP and TNFα were significant.
Conclusions:
Elevated cholesterol is a primary risk for NPS in males and inflammatory processes and oxidative stress primary
for females. Findings indicate the biomarkers of NPS are related to both gender and APOE4 status and these variables need to
be taken in account in the identification and treatment of AD patients at risk for NPS.
Biography
James Hall is a Professor of Psychiatry and Medicine in the Center for Alzheimer’s and Neurodegenerative Disease at the University of North Texas Health Science
Center. He had published over 100 peer reviewed articles and presents internationally at scientific meetings on Alzheimer’s disease and biomarkers. He is Director
of the Proteomics Laboratory and Director of the Memory Disorders Clinic at the University of North Texas Health Science Center.
James.hall@unthsc.eduJames Hall, J Proteomics Bioinform 2017, 10:12(Suppl)
DOI: 10.4172/0974-276X-C1-110